cryptosporidium
parvum
unicellular
zoonot
agent
infect
wide
rang
host
human
cattl
goat
caus
sever
wateri
diarrhoea
often
selflimit
also
fatal
outcom
young
calv
c
parvum
common
caus
diarrhoea
affect
nearli
everi
anim
et
al
consequ
calv
suppos
major
sourc
oocyst
infect
human
especi
rural
area
poor
sanit
close
contact
human
livestock
recent
global
enter
multicent
studi
gem
identifi
cryptosporidium
sp
second
common
pathogen
children
moder
sever
diarrhoea
cryptosporidium
significantli
associ
increas
risk
death
children
kotloff
et
al
unfortun
treatment
option
cryptosporidium
infect
limit
two
approv
product
market
moder
effect
cryptosporidium
nitazoxanid
approv
usa
treat
human
halofuginon
approv
europ
treatment
calv
lendner
et
al
calciumdepend
protein
kinas
cdpk
plantderiv
kinas
differ
mammalian
kinas
enlarg
adenosin
triphosph
atp
bind
pocket
select
inhibit
bump
kinas
inhibitor
bki
castellanosgonzalez
et
al
orthologu
toxoplasma
gondii
shown
play
crucial
role
invas
lourido
et
al
consequ
bki
develop
prevent
invas
inhibit
cdpk
function
lourido
et
al
ojo
et
al
johnson
et
al
gondii
shown
bki
select
target
overexpress
mutant
form
mutant
gondii
display
decreas
sensit
bki
ojo
et
al
shown
bki
potent
inhibitor
prevent
invas
host
cell
c
parvum
vitro
establish
diseas
mice
castellanosgonzalez
et
al
howev
c
parvum
infect
immunocompet
mice
make
transfer
result
experi
use
immunosuppress
mice
natur
host
difficult
demonstr
first
time
bki
reduc
c
parvum
oocyst
shed
natur
host
three
group
n
newborn
calv
infect
singl
dose
c
parvum
oral
treat
five
time
everi
day
mganim
bki
mock
control
solvent
ethanol
dmso
milk
replac
start
h
infect
oocyst
output
semiquantit
analysi
accord
keidel
daugschi
health
statu
assess
daili
doubleblind
studi
averag
oocyst
output
per
anim
per
field
vision
calcul
sum
oocyst
output
group
studi
day
divid
number
anim
per
group
singl
dose
infect
c
parvum
led
mild
symptom
day
wateri
diarrhoea
group
untreat
group
one
anim
exclud
die
studi
day
due
bacteri
infect
one
anim
treatment
group
die
studi
day
due
omphalogen
system
infect
associ
patent
urachu
bki
anim
show
singl
peak
oocyst
excret
day
pi
wherea
control
group
show
second
much
higher
peak
day
pi
overal
reduct
oocyst
shed
bki
group
compar
mock
control
group
compar
untreat
group
see
tabl
studi
show
bki
might
potenti
treat
cryptosporidiosi
calv
potenti
human
well
howev
minor
differ
faecal
consist
dehydr
could
observ
treatment
group
control
group
due
fact
infect
c
parvum
gener
moder
term
diarrhoea
dehydr
even
control
seven
anim
one
two
cohort
experi
bloodi
faec
unusu
c
parvum
monoinfect
make
like
anim
infect
undetect
enteropathogen
sinc
sever
cryptosporidiosi
calv
may
reflect
multifactori
aetiolog
et
al
analys
faecal
sampl
common
enteropathogen
rotaviru
coronaviru
escherichia
coli
giardia
commerci
avail
fast
test
rotaviru
coronaviru
e
coli
strip
test
bio
x
diagnost
giardia
elisa
sampl
neg
pathogen
howev
exclud
presenc
enteropathogen
clostridium
perfringen
caus
enter
howev
studi
need
evalu
bki
would
reduc
symptom
set
anim
develop
long
last
day
moder
sever
diarrhoea
without
coinfect
sinc
cryptosporidiosi
multifactori
diseas
sever
symptom
occur
predominantli
coinfect
anim
et
al
would
also
necessari
test
bki
would
lead
improv
coinfect
altogeth
studi
show
bki
could
potenti
treat
cryptosporidiosi
calv
might
also
candid
treat
human
specif
bki
target
human
protein
kinas
castellanosgonzalez
et
al
make
highli
probabl
relev
side
effect
would
occur
human
case
calv
experi
